Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | PKLR | P30613 | 2/20 | 0.35 |
| ▸ | PLK1 | P53350 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129222 | 0.85 | NR1H4 (0.46) | NR1H4PKMPKLRSMN1; SMN2POLB | |
| SCHEMBL5128146 | 0.82 | NR1H4 (0.64) | NR1H4PKMPKLRSMN1; SMN2MAPT | |
| SCHEMBL5120861 | 0.78 | MAPT (0.35) | NR1H4PKMPKLRSMN1; SMN2POLB | |
| SCHEMBL5127369 | 0.78 | NR1H4 (0.41) | NR1H4PKMPKLRSMN1; SMN2POLB | |
| SCHEMBL5121816 | 0.78 | PKM (0.43) | PKMPKLRSMN1; SMN2POLBMAPT | |
| SCHEMBL5124135 | 0.78 | MEN1 (0.36) | NR1H4PKMPKLRSMN1; SMN2POLB | |
| SCHEMBL5122230 | 0.77 | BRD4 (0.51) | NR1H4SMN1; SMN2MAPTBRD4GAA | |
| SCHEMBL5122911 | 0.76 | NR1H4 (0.44) | NR1H4SMN1; SMN2POLBMAPTGAA | |
| SCHEMBL5116591 | 0.76 | GAA (0.49) | NR1H4PKMPKLRSMN1; SMN2POLB | |
| SCHEMBL5127878 | 0.76 | MAPK14 (0.41) | NR1H4PKMSMN1; SMN2MAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7420056-B2 | Substituted bicyclic imidazo-3-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | GRUENENTHAL GMBH. (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155965-A1 | SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | NR1H4 2683/4885PKM 196/4885PKLR 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.